Sort
4,870 grants matching “glp 1”
Lentivirus-based Immunogene Therapy for HIV Infection
$1,931,956Carl H. June · University Of Pennsylvania · U19 · FY2008 · AI
Lentivirus-based Immunogene Therapy for HIV Infection
$1,931,956Carl H. June · University Of Pennsylvania · U19 · FY2007 · AI
Influenza vaccination using a microneedle patch
$1,928,072Mark R Prausnitz · Georgia Institute Of Technology · U01 · FY2014 · EB
First-In-Human Study of a Humanized Anti-Cocaine Monoclonal Antibody
$1,925,827Andrew B Norman · University Of Cincinnati · U01 · FY2020 · DA
Development of a recombinant protein vaccine for Chlamydia trachomatis
$1,925,693Toni Darville · Univ Of North Carolina Chapel Hill · U01 · FY2025 · AI
First in Human Study of a Tau Self-Association Small Molecule Inhibitor in Healthy Volunteers
$1,917,889William A. Erhardt · Oligomerix, Inc · R01 · FY2022 · AG
Core 4: Regulatory Compliance
$1,916,667Ronald B Corley · Boston University Medical Campus · UC7 · FY2021 · AI
Evaluation of Optimized Lead Candidates for Encephalitic Alphaviruses in Animal Models
$1,901,521Colleen B Jonsson · University Of Tennessee Health Sci Ctr · U19 · FY2019 · AI
In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response
$1,898,361Worapol Ngamcherdtrakul · Pdx Pharmaceuticals, Inc. · R44 · FY2021 · CA
Development of transapical MVAD for heart failure therapy
$1,891,204Daniel Tamez · Heartware, Inc. · R44 · FY2014 · HL
Nonalcoholic Steatohepatitis: Natural History, Pathogenesis and Therapy
$1,885,349Yaron Rotman · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK
Translational Gene Therapy for Rhodopsin Autosomal Dominant Retinitis Pigmentosa
$1,876,891William A. Beltran · University Of Pennsylvania · R24 · FY2016 · EY
Elafin Therapy for Pulmonary Arterial Hypertension
$1,870,546Marlene Rabinovitch · Stanford University · P01 · FY2018 · HL
Silica Nanocapsule-Mediated Nonviral Delivery of CRISPR Base Editor mRNA and Allele Specific sgRNA for Gene Correction in Leber Congenital Amaurosis
$1,866,136Shaoqin - Gong · University Of Wisconsin-Madison · U19 · FY2023 · NS
Medicinal Chemistry Optimization of Anti-Alphaviral Leads and Elucidation of Target and Off Target Engagement
$1,865,824Jennifer E. Golden · University Of Tennessee Health Sci Ctr · U19 · FY2021 · AI
Targeting galectin-3 to overcome insulin resistance in type 2 diabetes
$1,864,171Hafiz Ahmed · Glycomantra, Inc. · R44 · FY2024 · DK
New tools from chemistry and antibodies to address receptor function
$1,848,554Ross Cheloha · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK
Translational Gene Therapy for Rhodopsin Autosomal Dominant Retinitis Pigmentosa
$1,840,747William A. Beltran · University Of Pennsylvania · R24 · FY2015 · EY
Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease
$1,840,246Sean Ekins · Collaborations Pharmaceuticals, Inc. · SB1 · FY2024 · NS
Translational Gene Therapy for CNGB1 Retinitis Pigmentosa
$1,832,126Simon Petersen-Jones · Michigan State University · R24 · FY2020 · EY
Small Molecule Inhibitors of Smallpox Virus Replication
$1,829,082Robert Jordan · Siga Technologies, Inc. · R44 · FY2008 · AI
Translational Gene Therapy for CNGB1 Retinitis Pigmentosa
$1,828,029Simon Petersen-Jones · Michigan State University · R24 · FY2021 · EY
Development of an M1 PAM experimental therapeutic for schizophrenia
$1,827,730P Jeffrey Conn · Vanderbilt University · U19 · FY2016 · MH
Targeting galectin-3 to overcome insulin resistance in type 2 diabetes
$1,810,483Hafiz Ahmed · Glycomantra, Inc. · R44 · FY2023 · DK
Preclinical development of a precision therapy for a monogenic mental health disorder
$1,806,486Courtney A Miller · University Of Florida · U01 · FY2025 · MH